Orion Infusion Limited (DSE:ORIONINFU)

Market Cap	7.43B
Revenue (ttm)	631.54M
Net Income (ttm)	35.63M
Shares Out	20.36M
EPS (ttm)	1.75
PE Ratio	208.56
Forward PE	n/a
Dividend	2.00 (0.55%)
Ex-Dividend Date	Dec 2, 2025

Volume	296,382
Average Volume	318,226
Open	372.00
Previous Close	379.60
Day's Range	349.00 - 374.40
52-Week Range	265.40 - 587.50
Beta	-2.41
RSI	40.61
Earnings Date	Nov 9, 2025

About Orion Infusion

Orion Infusion Limited manufactures and sells large volume parenteral and other lifesaving injectable products in Bangladesh. The company offers I.V. rehydration, electrolyte, and acidosis solutions; ranitidine I.V. infusion; anti-microbial products; metronidazole I.V; pure steam generated fluids; and amino acids solution. It also provides sterile and nonpyrogenic solution, such as Dextrolac, Dianak, Hartman, Manisol, Plasmasol, and Proliv; hypertonic solution, including Dextrosal, Electrodex-10, Fructose – 10, Orlev, Ortac; Dextropac, an isoto...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 563
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ORIONINFU

Financial Performance

In 2025, Orion Infusion's revenue was 664.92 million, a decrease of -19.64% compared to the previous year's 827.42 million. Earnings were 35.02 million, a decrease of -17.27%.